Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Helix, the leading enterprise genomics company, today announced a multi-year strategic collaboration with GSK, the global biopharma company. This agreement provides GSK access to Helix's continuously ...

GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of precision medicines. The announcement comes on the heels of FDA’s approval of ...

International drug developer GSK is leaving a massive Rockville research and development facility that was custom-made for a company it acquired. With the move, the company is expanding its presence ...

In today’s Pharma Pulse, over 200 health groups denounce childhood vaccine schedule cuts, GSK acquires RAPT Therapeutics, and ...

Futurestep to provide recruitment services across the UK, US and Latin America Futurestep division of Korn Ferry (NYSE:KFY), the preeminent global people and organisational advisory firm, has been ...

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...